Publisher's Synopsis
Presents evidence that letrozole, anastrozole, and exemestane have proven efficacy as second-line therapy and indicate increased antitumor effects and less toxicity than older aromatase inhibitors and progestins!
This reference provides a state-of-the-art assessment of drugs that inhibit the synthesis of estrogens-particularly agents used to treat breast cancer-and demonstrates how the endocrinological effects of the new generation of inhibitors translate into clinical benefits.
Highlights recent key research aimed at developing novel reagents and technology to optimize drug therapies and expand their clinical applications.
With contributions from over 75 international experts, Aromatase Inhibition and Breast Cancer
Given the remarkable endocrine effects and the clinical potential of the new generation of aromatase inhibitors, Aromatase Inhibition and Breast Cancer is an essential reference for oncologists, endocrinologists, gynecologists, obstetricians, pharmacologists, family physicians, reproductive biologists, and medical school students in these disciplines.
